Patents by Inventor Alice Rico
Alice Rico has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9694016Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: March 13, 2014Date of Patent: July 4, 2017Assignee: NOVARTIS AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele Nishiguchi, Yue Pan, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Sharadha Subramanian, Benjamin Taft, Huw Tanner, Lifeng Wan, Naeem Yusuff
-
Publication number: 20160038504Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Applicant: NOVARTIS AGInventors: Robert AVERSA, Paul A. BARSANTI, Matthew BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele NISHIGUCHI, Yue PAN, Valery POLYAKOV, Savithri RAMURTHY, Alice RICO, Lina SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin TAFT, Huw TANNER, Lifeng WAN, Naeem YUSUFF
-
Patent number: 9242969Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: March 11, 2014Date of Patent: January 26, 2016Assignee: Novartis AGInventors: Paul A. Barsanti, Matthew Burger, Yan Lou, Gisele Nishiguchi, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Benjamin Taft, Huw Tanner, Alan DiPesa, Naeem Yusuff
-
Publication number: 20150336960Abstract: The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: December 7, 2013Publication date: November 26, 2015Applicant: NOVARTIS AGInventors: Matthew BURGER, Gisele NISHIGUCHI, Alice RICO, Benjamin TAFT
-
Patent number: 9173883Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: GrantFiled: May 20, 2013Date of Patent: November 3, 2015Assignee: NOVARTIS AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20150150873Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: February 12, 2015Publication date: June 4, 2015Inventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20150133473Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: May 20, 2013Publication date: May 14, 2015Applicant: NOVARTIS AGInventors: Matthew Burger, Joseph E. Drumm III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Patent number: 8987457Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: GrantFiled: May 20, 2013Date of Patent: March 24, 2015Assignee: Novartis AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20140275003Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: NOVARTIS AGInventors: Paul A. Barsanti, Matthew Burger, Yan Lou, Gisele Nishiguchi, Valery Polyakov, Savithri Ramurthy, Alice Rico, Lina Setti, Aaron Smith, Benjamin Taft, Huw Tanner, Alan DiPesa, Naeem Yusuff
-
Publication number: 20140228363Abstract: The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: April 22, 2014Publication date: August 14, 2014Applicant: NOVARTIS AGInventors: Matthew Burger, Yu Ding, Wooseok Han, Gisele Nishiguchi, Alice Rico, Robert Lowell Simons, Aaron R. Smith, Victoriano Tamez, JR., Huw Tanner, Lifeng Wan
-
Publication number: 20130336965Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: May 20, 2013Publication date: December 19, 2013Applicant: Novartis AGInventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
-
Publication number: 20130109682Abstract: The present invention provides certain compounds of Formula (I): and pharmaceutically acceptable salts thereof, as further described herein. Also provided are formulations comprising compounds of formula I, and a method to use such compounds for treating a disease or condition mediated by Provirus Integration of Maloney Kinase (PIM Kinase), GSK3, PKC, KDR, PDGFRa, FGFR3, FLT3, or cABL.Type: ApplicationFiled: July 4, 2011Publication date: May 2, 2013Applicant: NOVARTIS AGInventors: Matthew Burger, Yu Ding, Wooseok Han, Mika Lindvall, Gisele A. Nishiguchi, Alice Rico, Aaron Smith, Huw Tanner, Lifeng Wan
-
Publication number: 20120225061Abstract: The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: March 1, 2012Publication date: September 6, 2012Inventors: Matthew Burger, Yu Ding, Wooseok Han, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Aaron R. Smith, Victoriano Tamez, JR., Huw Tanner, Lifeng Wan
-
Publication number: 20120225062Abstract: The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.Type: ApplicationFiled: March 2, 2012Publication date: September 6, 2012Inventors: Matthew Burger, Gisele Nishiguchi, Timothy D. Machajewski, Alice Rico, Robert Lowell Simmons, Aaron R. Smith, Victoriano Tamez, JR., Huw Tanner, Lifeng Wan
-
Patent number: 7932262Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.Type: GrantFiled: April 5, 2007Date of Patent: April 26, 2011Assignee: Novartis AGInventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice Rico, Xiaojong M. Wang, Rama Jain, Jeremy M. Murray, Stephen E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng
-
Publication number: 20100216767Abstract: The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.Type: ApplicationFiled: December 20, 2007Publication date: August 26, 2010Inventors: Mina Aikawa, Payman Amiri, Steven Bashman, Jeffrey Dove, Rama Jain, Xiaodong Lin, Jeremy Murray, Savithri Ramurthy, Alice Rico, Wei Shu, Sharadha Subramanian, Xiaojing Michael Wang, Robert L. Warne, Yasheen Zhou
-
Publication number: 20100121052Abstract: The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.Type: ApplicationFiled: June 9, 2009Publication date: May 13, 2010Inventors: Rama Jain, Xiaodong Lin, Simon C. Ng, Keith B. Pfister, Savithri Ramurthy, Alice Rico, Sharadha Subramanian, Xiaojing Michael Wang
-
Patent number: 7671059Abstract: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.Type: GrantFiled: September 28, 2006Date of Patent: March 2, 2010Assignee: Novartis AGInventors: Timothy D. Machajewski, Cynthia M. Shafer, Christopher McBride, William Antonios-McCrea, Brandon M. Doughan, Barry H. Levine, Yi Xia, Maureen McKenna, X. Michael Wang, Kris Mendenhall, Yasheen Zhou, Kristin Brinner, Zhenhai Gao, Daniel Poon, Paul Barsanti, Xiaodong Lin, Abran Costales, Alice Rico, Nathan Brammeier, Teresa Pick, Paul A. Renhowe
-
Publication number: 20100004237Abstract: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.Type: ApplicationFiled: July 31, 2009Publication date: January 7, 2010Inventors: Timothy D. Machakewski, Cynthia M. Shafer, Christopher McBride, William Antonios-McCrea, Brandon M. Doughan, Barry H. Levine, Yi Xia, Maureen McKenna, X. Michael Wang, Kris Mendenhall, Yasheen Zhou, Baoqing Gong, Dan Gu, John Dolan, John Tulinsky, Kristin Brinner, Zhenhai Gao, Daniel Poon, Paul Barsanti, Xiaodong Lin, Abran Costales, Alice Rico, Nathan Brammeier, Teresa Pick, Paul A. Renhowe
-
Patent number: 7470701Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.Type: GrantFiled: March 30, 2005Date of Patent: December 30, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Xiaodong Lin, Alice Rico, Xiaojing Michael Wang, Yasheen Zhou, Ann B. Jefferson, Annette Walter